Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01398306

Acronym

BANN

Enrollment

Registered

2011-07-20

Start date

2011-07-31

Completion date

2012-04-30

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoid Tumor, Carcinoma, Carcinoma, Renal Cell, Neuroendocrine Tumors, Pancreatic Islet Cell Tumors

Keywords

Angiogenesis Inhibitors, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Adenocarcinoma, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Angiogenesis Inducing Agents, Biological Markers

Brief summary

The primary objective of this study is to analyse the concentration dopamine and serotonin in thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to the concentrations of these catecholamines in healthy volunteers. The concentration dopamine and serotonin in thrombocytes with and without medication will also be evaluated.

Detailed description

* To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours. * To compare these concentrations with the concentrations catecholamines in thrombocytes of healthy controls. * To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and patients with low grade neuroendocrine tumours with and without medication.

Interventions

OTHERBlood sampling by vena punction.

We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age 18 years old or older. * Patients with clear cell renal cell carcinoma with metastases or patients with a low-grade neuro-endocrine tumor with metastases. * Written informed consent

Exclusion criteria

* Use of L-dopa or SSRI. * Patients with a second primary malignancy.

Design outcomes

Primary

Measure	Time frame
Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.	one year

Secondary

Measure	Time frame
Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication.	one year

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026